136 related articles for article (PubMed ID: 17428156)
1. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
2. Tirofiban for myocardial infarction.
Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
[TBL] [Abstract][Full Text] [Related]
3. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.
Valgimigli M; Bolognese L; Anselmi M; Campo G; Rodriguez AE; de Cesare N; Cohen DJ; Sheiban I; Colangelo S; Pasquetto G; Hamon M; Vranckx P; Ferrario M; Prati F; Agostoni P; Malagutti P; Arcozzi C; Parrinello G; Vassanelli C; Ferrari R; Percoco G
Am Heart J; 2007 Jul; 154(1):39-45. PubMed ID: 17584549
[TBL] [Abstract][Full Text] [Related]
4. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Lakkis N; Lakiss N; Bobek J; Farmer J
Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
[TBL] [Abstract][Full Text] [Related]
7. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Danzi GB; Capuano C; Sesana M; Baglini R
Catheter Cardiovasc Interv; 2004 Feb; 61(2):179-84. PubMed ID: 14755808
[TBL] [Abstract][Full Text] [Related]
8. Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.
Lepor NE
Rev Cardiovasc Med; 2002; 3 Suppl 1():S3-S12. PubMed ID: 12439431
[TBL] [Abstract][Full Text] [Related]
9. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.
van 't Hof AW; Valgimigli M
Drugs; 2009; 69(1):85-100. PubMed ID: 19192938
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
[TBL] [Abstract][Full Text] [Related]
12. Tirofiban in acute coronary syndromes.
Menozzi A; Merlini PA; Ardissino D
Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):193-206. PubMed ID: 15853593
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
14. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
15. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
De Luca G; Marino P
Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
[TBL] [Abstract][Full Text] [Related]
16. Platelet glycoprotein IIb/IIIa inhibitors.
Rosove MH
Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
[TBL] [Abstract][Full Text] [Related]
17. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
[TBL] [Abstract][Full Text] [Related]
18. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK
Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
